Trump fast-tracks psychedelic research

The executive order directs the FDA to expedite the review of plant-based psychedelics, including ibogaine, which has been highlighted by veteran groups for its potential in treating PTSD. While the decision has been welcomed by some mental health advocates, medical experts have warned about the serious heart risks associated with unregulated use.

The administration's shift in policy marks a significant departure from traditional drug enforcement priorities.

Trump's engagement with Rogan on the issue underscores the influence of alternative media on White House decision-making.